Hyperion Defi, Inc. (NASDAQ: HYPD)

Hyperion DeFi, Inc. is a U. S. publicly listed company that pursues two main lines of business: building a strategic treasury of the Hyperliquid blockchain’s native token HYPE and developing the Optejet ophthalmic liquid delivery device. The company seeks to give shareholders simplified exposure to the high yielding Hyperliquid ecosystem while advancing a novel drug delivery technology for eye care.

Revenue is generated primarily from staking HYPE tokens, validator commissions earned through the Kinetiq and Hyperion validator node, and fee sharing arrangements under its HYPE Asset Service (HAUS) agreements with partners such as Credo Cayman, Felix and Native Markets. Additionally, the company plans to monetize the Optejet device through licensing or sales agreements, which could provide future product revenue.

The company operates through the following segments.

• Digital Assets: This segment encompasses the acquisition and staking of HYPE, operation of a validator node, and the HAUS service that supplies HYPE to third party DeFi protocols for reduced trading fees and other on chain utilities.

• Ophthalmic Technology: This segment focuses on the development, regulatory approval and commercialization of the Optejet user filled device, which delivers topical ophthalmic liquids with a low volume micro droplet spray.

In the digital asset space, Hyperion DeFi differentiates itself as the first U. S. public company to hold a dedicated HYPE treasury and to run its own validator, giving it direct access to staking yields and governance participation. In ophthalmics, the Optejet device offers a novel delivery mechanism that aims to improve patient compliance compared with traditional eye drops, positioning the company against established ophthalmic device manufacturers.

The Digital Assets segment serves institutional investors, DeFi protocol operators and cryptocurrency traders who seek exposure to HYPE based yield and reduced trading fees, including named partners such as Credo Cayman, Felix, Native Markets, Kinetiq and Pier Two. The Ophthalmic Technology segment targets eye care professionals, clinics and patients who use topical ocular medications, although specific customer names have not been disclosed.